Abstract
Billions of doses of vaccines are administered globally each year, saving millions of lives. Although traditional platforms have included inactivated, protein subunit, and viral vector vaccines, novel mRNA vaccine technology permitted rapid development of SARS-CoV-2 vaccines that were deployed at scale during the COVID-19 pandemic, and clinical application and development of mRNA therapeutics for other diseases have been rapidly advancing (1). In their article, Riddler and colleagues present safety results from a phase 1, randomized, open-label clinical trial (HVTN 302 [ClinicalTrials.gov: NCT05217641]) of investigational HIV-1 BG505 MD39.3 trimer mRNA vaccines
